12 December 2024
12 December 2024
The push to replace Albert Bourla as Pfizer’s CEO drew attention from the pharma industry but was soon derailed by several events.
A clinical trial will be conducted next year to establish a “clear evidence base” while a broader review will take place in 2027.
When a room of physicians at ASH 2024 was asked whether they had prescribed a gene therapy in a commercial context, only a handful said yes.
The rights were obtained through an exclusive licence and supply agreement with Hong Kong King-Friend Industrial.
A cornerstone of the investment is the launch of Europe’s first Lilly Gateway Labs.
The candidates merge two existing vaccines that have demonstrated favourable tolerability through randomised controlled studies.
The initial exclusive distribution arrangement was announced in January 2024.
If accepted, Vifor Pharma's £23m offer will "claw back" money for the NHS and close the CMA's first-ever disparagement case.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
